Journal of Antimicrobial Chemotherapy (1996) 37, 361-364
© 1996 The British Society for Antimicrobial Chemotherapy
brief-report |
Comparative in-vitro activity of SCH 27899, a novel eveminomicin, and vancomycin
aDepartment of Medicine, The New York Hospital, Medical Center of Queens Flushing, New York 11355-5095 bDepartments of Medicine, Cornell University Medical College USA cMicrobiology, Cornell University Medical College USA
Received 7 June 1995; returned 17 August 1995; accepted 20 September 1995
The antibacterial activity of SCH 27899, was compared with vancomycin in vitro against 210 recent clinical isolates representing eight major genera of Gram-positive organisms. MIC90 values for everninomicin were consistently better than those of vancomycin for all Gram-positive bacteria tested. Although everninomicin was less bactericidal than vancomycin against staphylococci, it was inhibitory against vancomycin-resistant enterococci. This novel antibiotic may, therefore, provide a clinical alternative to penicillin and vancomycin for therapy of Gram-positive infections.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. M. Aarestrup and P. M. McNicholas Incidence of High-Level Evernimicin Resistance in Enterococcus faecium among Food Animals and Humans Antimicrob. Agents Chemother., September 1, 2002; 46(9): 3088 - 3090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hallgren, H. Abednazari, C. Ekdahl, H. Hanberger, M. Nilsson, A. Samuelsson, E. Svensson, L. E. Nilsson, and t. Swedish ICU Study Group Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems J. Antimicrob. Chemother., July 1, 2001; 48(1): 53 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Miyazaki, K. Tateda, T. Matsumoto, A. Ohno, Y. Ishii, N. Furuya, and K. Yamaguchi In vitro antimicrobial activities of a novel everninomicin for multiple drug-resistant Streptococcus pneumoniae isolates in Japan J. Antimicrob. Chemother., June 1, 2001; 47(6): 900 - 901. [Full Text] [PDF]
|
|
|
|
|
|
R. N. Jones, R. S. Hare, F. J. Sabatelli, and T. Ziracin Susceptibility Testing Group In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial J. Antimicrob. Chemother., January 1, 2001; 47(1): 15 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. Boucher, C. Thauvin-Eliopoulos, D. Loebenberg, and G. M. Eliopoulos In Vivo Activity of Evernimicin (SCH 27899) against Methicillin-Resistant Staphylococcus aureus in Experimental Infective Endocarditis Antimicrob. Agents Chemother., January 1, 2001; 45(1): 208 - 211. [Abstract] [Full Text]
|
|
|
|
|
|
F. M. Aarestrup and L. B. Jensen Presence of Variations in Ribosomal Protein L16 Corresponding to Susceptibility of Enterococci to Oligosaccharides (Avilamycin and Evernimicin) Antimicrob. Agents Chemother., December 1, 2000; 44(12): 3425 - 3427. [Abstract] [Full Text]
|
|
|
|
|
|
M. Souli, C. Thauvin-Eliopoulos, and G. M. Eliopoulos In Vivo Activities of Evernimicin (SCH 27899) against Vancomycin-Susceptible and Vancomycin-Resistant Enterococci in Experimental Endocarditis Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2733 - 2739. [Abstract] [Full Text]
|
|
|
|
|
|
D. M. Livermore Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J. Antimicrob. Chemother., September 1, 2000; 46(3): 347 - 350. [Full Text] [PDF]
|
|
|
|
|
|
W. S. Champney and C. L. Tober Evernimicin (SCH27899) Inhibits both Translation and 50S Ribosomal Subunit Formation in Staphylococcus aureus Cells Antimicrob. Agents Chemother., June 1, 2000; 44(6): 1413 - 1417. [Abstract] [Full Text]
|
|
|
|
|
|
E. Wang, M. Simard, Y. Bergeron, D. Beauchamp, and M. G. Bergeron In Vivo Activity and Pharmacokinetics of Ziracin (SCH27899), a New Long-Acting Everninomicin Antibiotic, in a Murine Model of Penicillin-Susceptible or Penicillin-Resistant Pneumococcal Pneumonia Antimicrob. Agents Chemother., April 1, 2000; 44(4): 1010 - 1018. [Abstract] [Full Text]
|
|
|
|
|
|
P. C. Fuchs, A. L. Barry, and S. D. Brown In Vitro Activities of SCH27899 Alone and in Combination with 17 Other Antimicrobial Agents Antimicrob. Agents Chemother., December 1, 1999; 43(12): 2996 - 2997. [Abstract] [Full Text]
|
|
|
|
|
|
M. A. Schouten, A. Voss, J. A. A. Hoogkamp-Korstanje, and The European VRE Study Group Antimicrobial Susceptibility Patterns of Enterococci Causing Infections in Europe Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2542 - 2546. [Abstract] [Full Text]
|
|
|
|
|
|
L. L. Dever, C. V. Torigian, and A. G. Barbour In Vitro Activities of the Everninomicin SCH 27899 and Other Newer Antimicrobial Agents against Borrelia burgdorferi Antimicrob. Agents Chemother., July 1, 1999; 43(7): 1773 - 1775. [Abstract] [Full Text]
|
|